

## InnoCyto Inc.

15375 Barranca Pkwy, Suite I-103 Irvine, CA 92618

## **Technical Data Sheet**

FITC Anti-Mouse PD-L1

Catalog Number: 201309, 201310

Size: 25 tests, 100 tests

Target Name: CD274, PD-L1, B7-H1

Regulatory Status: RUO

#### **Product Details**

Clone: 10F.9G2
Application: FC
Reactivity: Mouse
Format: FITC
Isotype: Rat IgG2b

Antibody Type: Monoclonal

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v)

BSA

**Protein Concentration:** Supplied at a lot-specific concentration.

Storage and Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and

protected from prolonged exposure to light. Do not freeze.

**Recommended Usage:** For flow cytometric staining, it is recommended to use 5 uL of this reagent per 0.5-1.0 million cells in a 100 μL volume. Optimal reagent performance should be determined by

titration for each specific application. **Excitation Laser:** Blue Laser (488 nm)

### **Background Information**


PD-L1 (Programmed Death-Ligand 1), also known as CD274 or B7-H1, is a 40 kDa type I transmembrane protein belonging to the B7 family within the immunoglobulin receptor superfamily. The protein contains immunoglobulin V-like and C-like domains and is expressed by a wide range of hematopoietic and non-hematopoietic cells, including T cells, B cells, NK cells, dendritic cells, monocytes, endothelial cells, and various tumor cells. PD-L1 serves as a ligand for PD-1 (CD279) and plays a critical role in immune regulation by inhibiting T-cell activation, proliferation, and cytokine production upon engagement with PD-1. This interaction maintains immune homeostasis during infection or inflammation, preventing autoimmunity. However, in tumor microenvironments, PD-L1 expression enables immune evasion by suppressing cytotoxic T-cell function, contributing to tumor progression. PD-L1 expression is considered prognostic in several malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants. The PD-1/PD-L1 axis is a major target in cancer immunotherapy.

### **Product Data**



# InnoCyto Inc.

15375 Barranca Pkwy, Suite I-103 Irvine, CA 92618



Mouse splenocytes stained with either FITC anti-Mouse PD-L1 clone 10F.9G2 (blue histogram) or an isotype control (gray histogram).